A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects

June 24, 2021 updated by: Ratan K. Chaudhuri

Every day the cells of the outer layer of skin die off, shed, and regenerate. When young, skin cells turn over quickly, but that turnover rate begins to slow with age, beginning as early as twenties. As a result, skin loses its luster and begins to look dull. Aging caused by the genes is inherited and is called intrinsic (internal) aging. The other type of aging is known as extrinsic (external) aging and is caused by environmental factors, such as exposure to the sun's rays.

Skin ageing is mainly characterized by -

  1. Decrease in thickness, firmness & elasticity of skin which results in wrinkles.
  2. Reduction in antioxidant capacities.
  3. Formation of spider veins and dark circles under the eyes. This study is proposed to evaluate skin antiaging efficacy along with the brightening attributes on face by visual assessment by Dermatologist, image analysis using VISIA CR, skin elasticity by Cutometer (MPA580) Hydration by Corneometer and skin texture by Antera 3 D and skin lightening/fairness by spectrophotometer, water barrier function by TEWL and to skin pH level by pH meter.

Study Overview

Status

Completed

Conditions

Detailed Description

Every day the cells of the outer layer of skin die off, shed, and regenerate. When young, skin cells turn over quickly, but that turnover rate begins to slow with age, beginning as early as twenties. As a result, skin loses its luster and begins to look dull. Aging caused by the genes is inherited and is called intrinsic (internal) aging. The other type of aging is known as extrinsic (external) aging and is caused by environmental factors, such as exposure to the sun's rays.

Skin ageing is mainly characterized by -

  1. Decrease in thickness, firmness & elasticity of skin which results in wrinkles.
  2. Reduction in antioxidant capacities.
  3. Formation of spider veins and dark circles under the eyes.

The epidermis, dermis and subcutaneous tissues are the top, middle and bottom layers of the skin respectively. The top layer shows the wrinkles, age spots, deep lines, and depressions. The skin dermis contains macromolecules, polysaccharides, glycosaminoglycans (GAGs), fibrous protein (collagens, elastin), salts and water which together are known as the extra cellular matrix, responsible for tissue cohesion.

The subcutaneous tissues contain fatty deposits. Another part of the skin is the sebaceous glands that produce sebum which lubricates the skin and keeps it soft and smooth. All three skin layers contribute to the aging process. As a person gets older, less sebum is produced, and this makes the epidermis drier. Dry skin is more prone to wrinkling.

Signs of ageing include facial wrinkles, pigmentation, fine lines, crow's feet and Nasolabial folds. Ageing also impacts texture and elasticity of the skin.

Skin lightening or skin brightening, refer to the application of topical products in an attempt to lighten skin tone and provide an even skin complexion by reduction in melanin. The glow is not dependent on the skin colour of the person, i.e. a darker skin tone person can have very good Skin Glow. However, pigmentation errors like uneven skin tone, blemishes, blotchiness and spots also results in varied reflectance of light from the skin surface and results in dullness of the skin. It is also known that skin hydration, skin texture and pigmentation concerns can impact the skin glow. This study is based on evaluating Skin glow based on the relationship of these attributes.

This study is proposed to evaluate skin antiaging efficacy along with the brightening attributes on face by visual assessment by Dermatologist, image analysis using VISIA CR, skin elasticity by Cutometer (MPA580) Hydration by Corneometer and skin texture by Antera 3 D and skin lightening/fairness by spectrophotometer, water barrier function by TEWL and to skin pH level by pH meter.

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Karnatka
      • Bengaluru, Karnatka, India, 560008
        • MSCR

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

31 years to 46 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Female adult subjects in general good health as determined from a recent medical history, general physical examination, dermatological assessment.
  • Subjects in the age group of 35-50 years (both ages inclusive).
  • Subject with Fitzpatrick skin types III to V (ITA to be recorded at forehead and flexor forearm)
  • Subjects with chronic pollution exposure in past 5 years based on pollution questionnaire (Refer annexure 1)
  • Subjects with normal to dry skin type (corneometer reading upto 35)
  • Subjects with mild to moderate fine lines and wrinkles in periorbital area (Crow's feet-under eye) & forehead (Refer annexure 3 for photonumerical scale)
  • Subjects with minimum one spot with width ≥3 mm
  • Subjects with chronic pollution exposure in past 5 years based on pollution questionnaire (Refer annexure 1)
  • Subject free of excessive hair, acne, cuts, abrasions, fissures, wounds, lacerations, or any other active skin conditions on the face.
  • Subject who agrees not to use any other product/treatment/home remedy/ except the provided product on their face during the study period other than the test product.
  • Subjects who agree not to carry out bleaching or any other procedures including facial etc. on face during the study period.
  • Subjects who agree not to expose to excessive sun light. (Sun exposure not more than half an hour daily and during that time use of umbrella to cover face).
  • Subjects willing to give a voluntary written informed consent, photography release and agree to come for regular follow-up.
  • Subjects willing to abide by and comply with the study protocol.

Exclusion Criteria:

  • Subject with any other signs of significant local irritation or skin disease.
  • Subject currently taking any medication, which the Investigator believes may influence the interpretation of the data.
  • Subject having clinically significant systemic or cutaneous disease, chronic illness or had major surgery in the last year.
  • Subjects who do not agree to remove all jewellery on/around face (e.g., necklace, earrings, if possible nose ring), during VISIA imaging.
  • Subjects having hair style which covers almost the entire forehead
  • Subjects undergoing any treatment of any skin condition on their face/forearm.
  • Subjects not willing to discontinue other topical facial products.
  • Subject allergic or sensitive to bar cleansing products, cosmetics, creams/lotions, artificial jewellery or anything else.
  • Pregnant women (as confirmed by UPT) and lactating women
  • Subjects on any medical treatment either systemic/topical in the past 1 month or currently taking medication including food supplements.
  • Subjects with skin allergy history or atopic dermatitis or psoriasis
  • Subjects who have participated in any other clinical trial in the last 3 months.
  • Subjects using oral contraceptive pills or hormonal implants as birth control measures during the study
  • Subjects that was treated with Botox/filler /bio stimulatory molecules injection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Terminalia Chebula fruit extract

The test product is an emulsion. It contains Terminalia Chebula fruit extract.

Test product will be applied topically on full face twice a day for 8 weeks.

Standardized fruit extract
Placebo Comparator: Placebo

The placebo product is an emulsion with same appearance as the experimental product but without Terminalia Chebula fruit extract.

Placebo emulsion will be applied topically on full face twice a day for 8 weeks.

Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the investigational product for skin aging benefits
Time Frame: 8 weeks

Evaluate the antiaging effect of investigational product in 8 weeks w.r.t baseline in comparison to placebo as per below parameters.

i. Skin texture ii. Signs of aging iii. Skin elasticity/Firmness iv. Skin wrinkles and expression lines v. Skin dryness

8 weeks
Evaluate the investigational product for skin brightening benefits
Time Frame: 8 weeks

Evaluate the skin brightening benefit of investigational product in 8 weeks w.r.t. baseline in comparison to placebo as per below parameters.

i. Glow and radiance ii. Evenness iii. Clarity iv. Skin colour

8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the product safety and tolerance by skin tolerance evaluation by dermatologist.
Time Frame: 8 weeks
Evaluate the product safety and tolerance by skin tolerance evaluation by dermatologist.
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dr Mukesh Ramnane, MD, MSCR

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 3, 2020

Primary Completion (Actual)

January 20, 2021

Study Completion (Actual)

April 30, 2021

Study Registration Dates

First Submitted

February 14, 2020

First Submitted That Met QC Criteria

February 17, 2020

First Posted (Actual)

February 19, 2020

Study Record Updates

Last Update Posted (Actual)

June 25, 2021

Last Update Submitted That Met QC Criteria

June 24, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • SKIN/SYAS/2020-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Skin Aging

Clinical Trials on Placebo

Subscribe